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The dramatic recent rise in referrals to specialist memory clinics has been 
associated with an increased proportion of patients referred with Functional Memory 
Disorder (FMD), i.e.  non-progressive cognitive complaints. These referrals have 
exerted time and financial pressures on secondary care services, impairing their 
ability to deliver high-quality care for patients with neurodegenerative cognitive 
disorders.  We have developed a fully automated system, “CognoSpeak”, which 
enables risk stratification at the primary-secondary care interface and ongoing 
monitoring of patients with memory concerns. 
Methods 
We recruited 15 participants to each of four groups: Alzheimer’s disease (AD), Mild 
Cognitive Impairment (MCI), FMD and healthy controls. Participants responded to 12 
questions posed by a computer-presented talking head. Automatic analysis of the 
audio and speech data involved speaker segmentation, automatic speech 
recognition and machine learning classification.  
Results 
CognoSpeak could distinguish between participants in the AD or MCI groups and 
those in the FMD or healthy control groups with a sensitivity of 86.7%. Patients with 
MCI were identified with a sensitivity of 80%.  
Discussion  
Our fully automated system achieved levels of accuracy comparable to currently 
available, manually administered assessments. Greater accuracy should be 
achievable through further system training with a greater number of users, the 
inclusion of verbal fluency tasks and mood assessments. The current data supports 
CognoSpeak’s promise as a screening and monitoring tool for patients with MCI. 
Pending confirmation of these findings, it may allow clinicians to offer patients at low 




Memory clinics assess patients with a variety of cognitive complaints disorders, 
including those related to Alzheimer’s disease (AD), possible prodromal states (mild 
cognitive impairment, MCI) and those with Functional Cognitive Disorder (FCD, 
disabling but non-progressive cognitive complaints associated with emotional or 
psychological factors).  
Early referral to an appropriate care pathway yields benefits for patient wellbeing and 
efficient resource allocation. Specialist memory clinics are a limited resource and 
patients with FCD can be successfully managed in other settings. Accurate pre-clinic 
stratification tools are required to direct patients towards the most appropriate 
service. 
AD is associated with subtle impairments in language that may precede deficits in 
episodic memory by decades (1). Previous work has shown that qualitative analysis 
of conversational profiles inspired by the methodology of Conversation Analysis (CA) 
can discriminate between patients with FCD and those with neuro-degenerative (ND) 
conditions (2). However, this approach depends on highly trained experts and is not 
easily scalable.  
Whilst the use of automated speech analysis has been explored previously to 
identify cognitive impairment, most studies do not describe fully automated solutions. 
Instead, they rely on the automated analysis of data collected from human-human 
interaction (3) or used manually generated transcripts (4).  
We have created a fully automated stratification tool. “CognoSpeak” consists of a 
virtual clinician, a computer screen-presented talking head, which asks questions 
and records the patients’ spoken responses. The system uses Automatic Speech 
Recognition (ASR) and diarisation (segmenting the recording into contributions from 
different speakers) to extract acoustic and linguistic measures that are used by 
machine learning classifiers to select the most likely diagnostic category. (5). 
 
Methods  
We recruited 60 participants; 15 each from four different diagnostic groups: AD, MCI, 
FCD and healthy controls (HC). HCs were recruited via the “University of the Third 
Age” and patient participants from a specialist memory clinic in Sheffield, between 
May 2016 and January 2019. Patients could be recorded on their own or in the 
presence of an accompanying person. Ethical permission was granted by the NRES 
Committee South West-Central Bristol (Rec number 16/ LO/0737) in May 2016. 
Neurological diagnoses were made according to standard diagnostic criteria1 and 
after multidisciplinary team review. Presence of significant mood disturbance 
(ascertained through clinical history and Patient Health Questionnaire-9 (PHQ-9 > 
15) and significant cerebrovascular disease resulted in exclusion. All underwent 
cognitive assessment using Addenbrooke’s Cognitive Examination-Revision (ACE-
R) tool or detailed neuropsychological evaluation. Brain imaging (including CT, MRI 
and Tc99m HMPAO single-photon emission computed tomography) was performed 
based on clinical need. A proportion of the healthy control group had MRI as part of 
their involvement in a previous study (VPH-DARE@IT http://www.vph-dare.eu/).  
The CognoSpeak assessment process has been comprehensively described in prior 
papers (5). In brief, Participants were directed verbally to respond to the questions 
posed by the virtual clinician and to use the “enter” key to proceed from one question 
to the next. Audio data were recorded using a Tascam DR-40 recorder.  
                                                             
1 For AD, McKhann et al Alzheimer’s & Dementia, 2011; for MCI Petersen et al Archives of Neurology 1999, 
Petersen Archives of Neurology 2001; for FCD Schmidtke et al American Journal of Geriatric Psychiatry, 2008 
An ASR system was used to transcribe the audio into a string of words. A diarisation 
tool was then applied to provide annotation of which words were said by which 
speaker. The combined output of ASR and diarisation provided information on the 
content of the speech and the duration of the contributions of different speakers. The 
automatically transcribed text as well as the recorded audio were used to extract the 
range of features that the machine learning based classifier uses to assign 
participants to a diagnostic class. 
72 features were extracted from the speech of patients and accompanying persons, 




Please see Table 1 for demographic variables, psychological measures performed 
and the results and a description of the imaging. 
 
Table 1  
Characteristics HC FCD MCI AD 
Gender (% male) 40 40 66.7 66.7 
     
Age (Mean) 69.5 (± 4.0) 54.9 (± 4.1) 63.4 (± 4.2) 67.8 (± 4.2) † 




18.1 (± 1.0) 16.4 (±0.6) 17.3 (±1.1) 18 (±1.6)‡ 
     
Neuropsychology 
Performed (%) 
100 93.3 100 100 
ACE (%) 100 85.7 86.7 93.3 
MMSE (%)  14.3 13.3 6.7 
     
ACE Score 
(Mean) 
95.3 (± 1.6) 88.7 (± 5.9) 81.3 (± 3.6) 69.5 (± 8.2)* 
     
MMSE Score 
(Mean) 
 27.3 (± 1.9) 27.0 (± 0.8) 23 (± 3.3) 




40 86.8 100 100 
Abnormal (%) 0 20¥ 20 66.7 
Consistent with 
ND (%) 
0 0 13.3 26.7 
     
SPECT 
Performed (%) 
0 0 46.7 66.7 
Consistent with 
ND (%) 
0 0 85.7 70 
† Age: HC vs FCD, HC vs MCI, FCD vs MCI, FCD vs AD p <0.05. HC vs AD and MCI vs AD p >0.05 
‡ Years of Education: HC vs FCD and FCD vs AD p <0.05. HC vs MCI, HC vs AD, FCD vs MCI and MCI vs 
AD p <0.05 
* ACE Score: HC vs MCI, HC vs AD, FCD vs MCI, FCD vs AD and MCI vs AD p< 0.05. HC vs FCD p >0.05.  
¥ 3 Abnormal MRI scans demonstrating a previous contusional injury, generalised atrophy and mild 
small vessel disease. 
ND = Neurodegeneration  
 
The mean duration of interactions across all participant groups and CognoSpeak 
was 11 minutes 24 seconds. HCs spent an average of 9 minutes 58 seconds; FCD 
patients 11 minutes 2 seconds; MCI patients 9 minutes 34 seconds and AD patients 
15 minutes 2 seconds. Only the difference between the MCI vs AD groups was 
significant (U=59, P=0.026). 
 
Two-way automatic classification (AD & MCI v FMD & HC) 
An effective cognitive stratification tool must be able to separate those with potential 
neurodegeneration from those without. In the two-way classification CognoSpeak 
system had an accuracy of identifying participants with MCI or AD of 87% (see 
Figure 1a) whilst the accuracy of correctly allocating participants as either HC or 
FMD was 77%.  
Three-way automatic classification (AD v MCI v FMD & HC) 
Overall correct classification was achieved in 65% of cases. The accuracy of 
identifying participants with AD was 80% (see Figure 1b). Two participants were 
incorrectly allocated as MCI and one as belonging to the FMD and HC group.  
The identification accuracy of participants with MCI was 80%. One participant was 
incorrectly allocated as AD and two as FMD and HC. The accuracy of identifying the 
participants with either HC or FMD was 50%. Eight participants were incorrectly 
allocated as MCI and seven as AD.  
Four-way automatic classification (AD v MCI v FMD v HC) 
The more difficult task of identifying participants from all four groups revealed an 
overall classification accuracy of 60%.  Accuracy in identifying  AD participants was 
80%; accuracy in identifying MCI participants was 60%; accuracy in identifying  FCD 
participants was 47% and accuracy in identifying the HC participants was 53% 
(Figure 1-c), (of note the most frequent misclassifications occurred between the HC 
and FCD groups). 
 
Discussion  
The UK’s National Dementia Strategy emphasises the importance of early diagnosis 
and provision of support for patients with progressive cognitive disorders. Hence, our 
approach has prioritised sensitivity over specificity. The two-way classification 
system achieved a sensitivity of 86.7% for neurodegenerative memory disorders, 
comparing favourably with most commonly employed screening tools. The specificity 
was slightly lower at 76.7% but given the emphasis on early identification and the 
fact that “false positives” will be investigated by the specialist memory services, this 
is acceptable. Using a three-way classification MCI, AD & FCD plus HC) 
CognoSpeak was able to identify participants with MCI with a sensitivity of 80.0% 
(95% CI: 51.9-95.7) and a specificity of 77.8% (95% CI: 62.9-88.8), exceeding 
sensitivity (66.34%) and specificity (72.94%) of the MMSE in discerning between 
MCI and HCs (6). 
Accurate identification of patients with MCI may allow early intervention and facilitate 
participation in research studies. We are unaware of any other screening tool that 
has included patients with FCD in their development. However, the inclusion of this 
patient group is essential in validation studies of screening or stratification tools as 
those with FCD make up 24% of referrals to specialist memory services (7). The 
ability of our tool to distinguish between FCD and MCI / AD rather than only between 
HC and MCI/AD groups increases its ecological validity. The CognoSpeak 2-way 
classification system can distinguish between patients with MCI / AD and those 
without neurodegenerative pathology (HC & FCD) with a sensitivity of 86.7%. 
Typical pre-clinic cognitive screening tools take between 5-10 minutes and require 
clinician time (8, 9). CognoSpeak compares favourably to this. A large 2016 
systematic review described mean primary care physician consultation lengths 
across 67 countries. The group reported that 18 countries, accounting for 
approximately 50% of the world’s population, had mean GP consultation lengths of 5 
minutes or less (10). This suggests that even the most concise, traditional cognitive 
screening tool may not be applicable to a significant proportion of the world’s 
population. CognoSpeak has the advantage of being automated, capable of remote 
administration via a tablet in a primary care office or at home using a secure website, 
without the necessity for direct clinician oversight. It has been estimated that in 2019, 
58.8% of the global population have access to the internet (11). Results from at-
home screening could be transferred and analysed by local secondary care memory 
services, thus reducing primary care time. By identifying FCD this tool could be used 
to provide early reassurance and reduce the need for unnecessary and stressful 
memory clinic consultations. Furthermore, the results/reporting from CognoSpeak 
could triage those most at risk, plan scans before consultation and reduce the time 
needed for initial testing in specialist clinics. This may be especially important due to 
the accelerated use of telephone and virtual clinics, during the Covid-19 pandemic.  
Furthermore, the capacity of CognoSpeak to distinguish between patients with AD 
and MCI raises the possibility that this automated tool could be used for longitudinal 
monitoring of patients with MCI.  
We acknowledge a number of limitations to this study. The relatively small sample 
size was limited by the time taken to recruit well described participants in each 
cohort. A larger cohort would provide more accurate information into the relative 
sensitivity and specificity of CognoSpeak.  This analysis used the first 9 of 12 
questions posed. The remaining three questions, verbal fluency tasks and a picture 
description tasks, are extensively used in clinical practice, with good accuracy in 
detecting MCI. These will likely contribute to increasing accuracy of CognoSpeak. 
They have not been included in the current study as novel automated approaches to 
their analysis are still under development. Inherent to the iterative nature of the 
machine learning process, we anticipate attaining greater accuracy with access to 
larger sample sizes. This applies both to the accuracy of the automated speech 
recognition and the refinement of classifiers.  
For this initial validation study we have limited recruitment to patients belonging to 
the diagnostic groups most commonly represented in specialist memory clinics. 
Future studies will also include patient groups with non-AD dementias.  
In conclusion, CognoSpeak is a fully automated cognitive screening system that can 
discern between normal cognition and neurodegenerative memory disorders with 
sensitivity comparable to traditional screening methods.  
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